Deals
AstraZeneca Explores Potential Deal With Acerta for Cancer Drug
- Acerta's drug shows promise in leukemia, auto-immune diseases
- Credit Suisse predicts interest from `multiple other bidders'
Why Do Drug Prices Keep Going Up?
This article is for subscribers only.
AstraZeneca Plc said it’s exploring a deal with Acerta Pharma BV that would give the U.K. drugmaker a potential blockbuster medicine for blood cancers as well as diseases in which the body attacks itself.
Talks about “potential strategic options” with the closely held biotech company are ongoing but there’s no guarantee they will lead to a transaction, London-based AstraZeneca said in a statement.